Brand VerifiedUnited States

Merck & Co., Inc. (Animal Health Division)

Merck Animal Health

Merck Animal Health (MSD Animal Health outside North America) is the animal health powerhouse division of pharmaceutical giant Merck & Co., leveraging the parent company's $65.01 billion total revenue and $7+ billion annual R&D engine. Headquartered in Rahway, New Jersey, USA. With Animal Health revenue of USD 6.4 billion (2025), the division operates manufacturing in 50+ countries, supported by 75,000 parent-company employees. Merck Animal Health is currently executing the industry's most ambitious biologics capacity buildout, committing $895M to a 200,000 sq ft Kansas De Soto "Center of Excellence" and $185M to an Austria Krems multi-line vaccine facility.

Strengths:
• Parent Company Scientific Depth: Access to Merck & Co.'s $7B+ annual R&D spend and deep biologics expertise, creating unmatched scientific spillover into veterinary applications
• Blockbuster Parasiticide Portfolio: Bravecto series generated $11B in 2025 sales, establishing category leadership in long-duration parasiticides with 12-week protection duration
• Unprecedented Manufacturing Expansion: $895M Kansas De Soto and $185M Austria Krems concurrent facility expansions signal a long-term strategic commitment to owning the entire biologics value chain
• Diversified Revenue Base: Spanning companion animals, livestock, and newly acquired aquaculture business (post-$1.29B Elanco aqua acquisition), providing multi-segment cyclical resilience
• Regulatory Excellence: Deep institutional knowledge of FDA, EMA, and USDA approval pathways accelerates time-to-market for new animal drug applications
Weaknesses:
• Divisional Dependency: As a non-independent entity within Merck & Co., strategic capital allocation must compete with the human pharmaceutical portfolio's priorities
• Companion Animal Revenue Underweight: At $24.58B vs $38.96B livestock, the pet segment remains proportionally smaller relative to pure-play competitor Zoetis
• Clinic Visit Sensitivity: Certain quarters in 2025 saw companion animal sales stagnate as macroeconomic pressures reduced veterinary clinic visit frequency

Business Nature

Merck Animal Health leverages the vast infrastructure and R&D pipeline of its parent company Merck & Co. 2025 total revenue: $65.01 billion while operating as a dedicated animal health division. The division has embarked on an unprecedented capital expenditure program, committing $895 million to expand its De Soto, Kansas biologics manufacturing facility into a 200,000-square-foot "Center of Excellence" focused exclusively on large-molecule vaccines and advanced biologic fill/finish and freeze-drying capabilities.

In Europe, it acquired and is converting the former Baxter facility in Krems, Austria approximately €185 million investment into a multi-line animal vaccine production plant. With over 50 country-level direct operations and products reaching 150+ nations, Merck Animal Health maintains complete control over its core biologic manufacturing processes while benefiting from the parent company's $7+ billion annual R&D spend.

Core Business Areas

Companion Animal Portfolio — Core Business
• Parasiticides: Bravecto series 12-week duration
• Vaccines: Nobivac / Vanguard
• Anti-infectives: MOMETAMAX SINGLE otitis treatment
• Dermatology and specialty therapeutics
• Aquaculture health post-Elanco acquisition

Industry Rankings

2Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

2Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Merck Animal Health (MSD Animal Health) is the dedicated animal health division of Merck & Co., headquartered in Rahway, New Jersey, USA. The division leverages the parent company's $65.01 billion total revenue and $7+ billion annual R&D investment. In 2025, the Animal Health division generated USD 6.4 billion in global revenue, with products available in over 150 countries.

Core Business

Merck Animal Health's companion animal portfolio is anchored by the Bravecto series—the industry's premier long-duration (12-week) parasiticide franchise that generated $11B in 2025. The division also commands significant market share in companion animal vaccines (Nobivac, Vanguard) and recently launched the innovative MOMETAMAX SINGLE single-dose otitis treatment. Its livestock portfolio spans vaccines, anti-infectives, and fertility management products across bovine, porcine, poultry, and now aquaculture species.

Global Presence

With operations spanning 50+ countries and products reaching 150+ nations, Merck Animal Health's manufacturing footprint is undergoing a historic transformation. The $895M De Soto, Kansas expansion—situated in the heart of the US "Animal Health Corridor"—will add 200,000 square feet of dedicated large-molecule vaccine and biologic fill/finish capacity, creating 2,500+ construction jobs and 200+ permanent manufacturing positions by 2030. The concurrent €185M Austria Krems facility conversion adds multi-line vaccine production capability in Europe, representing a dual-continent biologics manufacturing strategy unmatched in the industry.

Key Strengths

• Backed by parent Merck & Co.'s $65B revenue and $7B+ annual R&D engine
• Bravecto franchise commanding $11B in 2025 parasiticide sales
• Historic $895M + $185M dual-continent biologics manufacturing expansion
• Diversified species portfolio spanning companion, livestock, and aquaculture
• Strategic acquisition of Elanco's global aquaculture business for $1.29B in 2024

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Rahway, New Jersey, USA

Founded

1940

Employees

75,000 (parent Merck & Co.)

Factories

Global manufacturing in 50+ countries; $895M Kansas De Soto expansion; $185M Austria Krems facility

Listing

NYSE: MRK (parent)

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: MRK (parent) , Merck Animal Health Official Website
SEC EDGAR — Merck & Co. Filings
Wikipedia — Merck & Co.

Back to Rankings